EBITDA: Income before interest, taxes, depreciation and amortization.
MoonLake Immunotherapeutics (MLTX) had EBITDA of $-70.69M for the most recently reported fiscal quarter, ending 2025-09-30.
| Income Statement Financials | |
-- |
|
$-69.73M |
|
-- |
|
-- |
|
$71.43M |
|
$-71.43M |
|
$0.85M |
|
$-70.58M |
|
$-70.58M |
|
$-70.69M |
|
$-70.69M |
|
$-70.69M |
|
$-70.69M |
|
$-71.43M |
|
|
EBITDA |
$-70.69M |
63.37M |
|
63.37M |
|
$-1.10 |
|
$-1.10 |
|
| Balance Sheet Financials | |
$411.21M |
|
$0.62M |
|
$3.12M |
|
$414.33M |
|
$48.37M |
|
$73.74M |
|
$74.78M |
|
$123.14M |
|
$291.19M |
|
$291.19M |
|
$291.19M |
|
64.23M |
|
| Cash Flow Statement Financials | |
$-137.21M |
|
$232.90M |
|
$73.60M |
|
$180.43M |
|
$350.74M |
|
$170.31M |
|
$9.31M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
8.50 |
|
-- |
|
-- |
|
0.20 |
|
0.25 |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
$-137.25M |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-24.28% |
|
-24.28% |
|
-17.06% |
|
-19.37% |
|
$4.53 |
|
$-2.17 |
|
$-2.17 |
|